The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Outcomes for Elderly, Advanced-Stage Non–Small-Cell Lung Cancer Patients Treated With Bevacizumab in Combination With Carboplatin and Paclitaxel: Analysis of Eastern Cooperative Oncology Group Trial 4599
Open accessAbstract
Purpose: Fit elderly patients with advanced non–small-cell lung cancer (NSCLC) benefit from platinum-based, two-drug chemotherapy. Bevacizumab (B) in combination with carboplatin (C) and paclitaxel (P) improves survival for advanced, nonsquamous NSCLC, as evidenced in Eastern Cooperative Oncology Group (ECOG) 4599. We conducted a subset analysis of ECOG 4599 to determine the outcome for elderly patients. Patients and Methods: ECOG 4599 randomly assigned patients with advanced nonsquamous NSCLC to PC or to PCB. We analyzed outcome in patients who were at least 70 years of age at the time of study entry. Patient characteristics, efficacy, and toxicity data were compared between PC and PCB for the elderly. Outcomes for elderly and younger patients (< 70 years) treated with PCB were also compared. Results: Among elderly patients (n = 224; 26%), there was a trend towards higher response rate (29% v 17%; P = .067) and progression-free survival (5.9 v 4.9 months; P = .063) with PCB compared with PC, although overall survival (PCB = 11.3 months; PC = 12.1 months; P = .4) was similar. Grade 3 to 5 toxicities occurred in 87% of elderly patients with PCB versus 61% with PC (P < .001), with seven treatment-related deaths in the PCB arm compared with two with PC. Elderly patients had higher incidence of grade 3 to 5 neutropenia, bleeding, and proteinuria with PCB compared with younger patients. Conclusion: In elderly NSCLC patients, PCB was associated with a higher degree of toxicity, but no obvious improvement in survival compared with PC. Data from this unplanned, retrospective analysis justify prospective evaluation of the therapeutic index of PCB regimen in elderly patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.43 · Cited by 7,439
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Self-citationComparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
Self-citationCOMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
Chiller, J. O. H. S., Arrington, D. A. H., Elani, C. H. P. B., Anger, C., Andler, A. L. S., Rook, J. A. K., Hu, J., & Ohnson, D. A. H. J. (2002) · Cited by 3,730
Govindan, R., Page, N., Morgensztern, D., Read, W., Tierney, R., Vlahiotis, A., Spitznagel, E. L., & Piccirillo, J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.4859 · Cited by 1,845
Elderly Lung Cancer Vinorelbine Italian Study Group (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.1.66 · Cited by 869
Gridelli, C., Perrone, F., Gallo, C., Cigolari, S., Rossi, A., Piantedosi, F., Barbera, S., Ferrau, F., Piazza, E., Rosetti, F., et al. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.5.362 · Cited by 781
Bonomi, P., Kim, K., Fairclough, D., Cella, D., Kugler, J., Rowinsky, E., Jiroutek, M., & Johnson, D. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.3.623 · Cited by 589
Self-citationHerbst, R. S., Johnson, D. H., Mininberg, E., Carbone, D. P., Henderson, T., Kim, E. S., Blumenschein, G., Lee, J. J., Liu, D. D., Truong, M. T., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.477 · Cited by 530
Self-citationLanger, C. J. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.3.173 · Cited by 502
Self-citationMeasuring comorbidity in older cancer patients
Extermann, M. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00319-6 · Cited by 476
Frasci, G., Lorusso, V., Panza, N., Comella, P., Nicolella, G., Bianco, A., De Cataldis, G., Iannelli, A., Bilancia, D., Belli, M., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.13.2529 · Cited by 447
Lilenbaum, R. C., Herndon, J. E., List, M. A., Desch, C., Watson, D. M., Miller, A. A., Graziano, S. L., Perry, M. C., Saville, W., Chahinian, P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.172 · Cited by 444
Jackman, D. M., Yeap, B. Y., Lindeman, N. I., Fidias, P., Rabin, M. S., Temel, J., Skarin, A. T., Meyerson, M., Holmes, A. J., Borras, A. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.5754 · Cited by 307
Measurement and impact of comorbidity in older cancer patients
Extermann, M. (2000) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(00)00090-1 · Cited by 299
Cancer and ageing: a nexus at several levels
Balducci, L., & Ershler, W. B. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1675 · Cited by 250
Manegold, C., von Pawel, J., Zatloukal, P., Ramlau, R., Gorbounova, V., Hirsch, V., Leighl, N., Mezger, J., Archer, V., & Reck, M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.lba7514 · Cited by 168
Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why?
Bunn, P. A. (2002) · PubMed · Cited by 154
Belani, C. P., & Fossella, F. V. (2005) · Cancer · doi:10.1002/cncr.21495 · Cited by 150
Self-citationHensing, T. A., Peterman, A. H., Schell, M. J., Lee, J., & Socinski, M. A. (2003) · Cancer · doi:10.1002/cncr.11548 · Cited by 135
Anti-Vascular Endothelial Growth Factor Monoclonals in Non-Small Cell Lung Cancer
Sandler, A. B., Johnson, D. H., & Herbst, R. S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-040023 · Cited by 125
Self-citationTreatment of Advanced Non–Small-Cell Lung Cancer With Two-Drug Combinations
Bunn, P. A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.17.3565 · Cited by 57
Cited by
Garon, E. B., Ciuleanu, T.-E., Arrieta, O., Prabhash, K., Syrigos, K. N., Goksel, T., Park, K., Gorbunova, V., Kowalyszyn, R. D., Pikiel, J., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60845-x · Cited by 1,309
Azzoli, C. G., Baker, S., Temin, S., Pao, W., Aliff, T., Brahmer, J., Johnson, D. H., Laskin, J. L., Masters, G., Milton, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.5622 · Cited by 915
Self-citationAdverse effects of anticancer agents that target the VEGF pathway
Chen, H. X., & Cleck, J. N. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.94 · Cited by 560
Lung cancer: New biological insights and recent therapeutic advances
Ramalingam, S. S., Owonikoko, T. K., & Khuri, F. R. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20102 · Cited by 471
Self-citationSoria, J.-C., Mauguen, A., Reck, M., Sandler, A. B., Saijo, N., Johnson, D. H., Burcoveanu, D., Fukuoka, M., Besse, B., & Pignon, J.-P. (2013) · Annals of Oncology · doi:10.1093/annonc/mds590 · Cited by 314
Metadata
- Authors
- Ramalingam, S. S., Dahlberg, S. E., Langer, C. J., Gray, R., Belani, C. P., Brahmer, J. R., Sandler, A. B., Schiller, J. H., & Johnson, D. H.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-01-01
- Volume
- 26
- Issue
- 1
- Pages
- 60-65
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2126310082
- Cited by
- 348
- References
- 23
- FWCI
- 26.56
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.